GE Healthcare Expands Precision Care with Acquisition of Nihon Medi-Physics

GE Healthcare has announced its acquisition of Nihon Medi-Physics (NMP), a Tokyo-based radiopharmaceutical company, by purchasing the remaining 50% stake from parent company Sumitomo Chemical. NMP specializes in radiopharmaceuticals used for imaging in neurology, cardiology, and oncology, with products like Vizamyl for detecting Alzheimer’s-related amyloid plaques and DaTscan for evaluating Parkinson’s disease or dementia. The move aligns with GE Healthcare’s strategic focus on radiopharmaceuticals as a growth driver alongside new product innovations and artificial intelligence, particularly in precision medicine markets like Japan. CEO Peter Arduini identified these areas as critical levers for company growth over the next three years.

NMP’s 13 manufacturing facilities and R&D capabilities will further GE Healthcare’s ability to develop proprietary and licensed imaging agents. With annual revenues of ¥28.2 billion (approximately $183 million) in 2023, NMP’s addition is expected to bolster GE Healthcare's footprint in the $7 billion global imaging market. The acquisition, expected to close in early 2025 pending regulatory approvals, will initially be neutral to adjusted earnings per share but is projected to become accretive over time. This deal builds on GE Healthcare’s long-standing involvement with NMP, dating back to its 2004 acquisition of Amersham, which included a partial stake in the firm.